LYEL:NASDAQ
Lyell Immunopharma Inc
8,12 $
arrow_downward
-0,85%(-0,070) 1D
8,12 $
0,00% (0,00)
bedtimeAfter hours
Closed: 16 հոկ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LYEL...
Open
8,24 $
High
8,44 $
Low
7,92 $
Mkt. cap
198,98 մլն
Avg. vol.
158,44 հզր
Volume
194,96 հզր
52-wk high
45,00 $
52-wk low
7,32 $
EPS
-12,01 $
Beta
-0,03
Shares outstanding
24,50 մլն
No. of employees
161
Open
8,24 $
High
8,44 $
Low
7,92 $
Mkt. cap
198,98 մլն
Avg. vol.
158,44 հզր
Volume
194,96 հզր
52-wk high
45,00 $
52-wk low
7,32 $
EPS
-12,01 $
Beta
-0,03
Shares outstanding
24,50 մլն
No. of employees
161
News stories
From web sources and news partners
KITV
·
52 րոպե առաջ
Nasdaq sinks more than 2% as investors raise questions about AI debt
MarketBeat
·
58 րոպե առաջ
Liberty Global (NASDAQ:LBTYA) Upgraded to Sell at Wall Street Zen
MarketBeat
·
58 րոպե առաջ
Penguin Solutions (NASDAQ:PENG) Upgraded at Wall Street Zen
MarketWatch
·
9 ժամ առաջ
Don’t buy this dip: Several signs suggest there’s more pain ahead for tech stocks
Profile
Lyell Immunopharma, Inc. is an American clinical-stage biopharmaceutical company headquartered in San Francisco, California. Founded in 2018, the company develops next-generation cell therapies, including CAR T cell, using technologies intended to improve T-cell persistence, function, and resistance to exhaustion. Its pipeline includes therapies being developed for hematologic malignancies and solid tumors. Wikipedia
About Lyell Immunopharma Inc
CEO-
Employees161
Founded2018
HeadquartersSouth San Francisco, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitelyell.com